Liver Function's impact on new drug explored

NCT ID NCT07144111

Recruiting now Knowledge-focused Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 23 times

Summary

This study looks at how moderate or severe liver problems change the way the body handles a single dose of the drug inavolisib. About 32 adults with and without liver impairment will take one dose, and researchers will measure drug levels and safety. The goal is to understand dosing needs for people with liver issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Orange County Research Center
RECRUITING

Lake Forest, California, 92630, United States
Orlando Clinical Research Center
RECRUITING

Orlando, Florida, 32809, United States
Pinnacle Clinical Research - San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
The Texas Liver Institute, Inc.
RECRUITING

San Antonio, Texas, 78215, United States

Conditions

Explore the condition pages connected to this study.

HEPATIC IMPAIRMENT